Literatur
- 1
De Luca G, Suryapranata H, Ottervanger J P, Antman E M.
Time delay to treatment and mortality in primary angioplasty for acute myocardial
infarction: Every minute of delay counts.
Circulation.
2004;
109
1223-1225
- 2
Morrison L J, Verbeek P R, Mc Donald A C. et al .
Mortality and prehospital thrombolyis for acute myocardial infarction.
JAMA.
2000;
283
2686-2692
- 3
Andersen H R, Nielsen T T, Rasmussen K. et al for the DANAMI-2 investigators .
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial
infarction.
N Engl J Med.
2003;
349
733-742
- 4
Antman E M, van de Werf F.
Pharmacoinvasive Therapy: The future of treatment for ST-Segment elevation myocardial
infarction.
Circulation.
2004;
109
2480-2486
- 5
Nallamothu B K, Bates E R, Herrin J. et al .
Times to treatment in transfer patients undergoing primary percutaneous coronary intervention
in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis.
Circulation.
2005;
111
761-767
- 6
Widimský P, Budésinský T, Vorac D. et al on behalf of the PRAGUE study group investigatora
.
Long distance transport for primary angioplasty vs immediate thrombolysis in acute
myocardial infarction. Final results of the randomized national multicentre trial
- PRAGUE-2.
Eur Heart J.
2003;
24
94-104
- 7
Steg P G, Bonnefoy E, Chabaud S. et al .
Impact of time to treatment on mortality after prehospital thrombolysis or primary
angioplasty: Data from the CAPTIM randomized trial.
Circulation.
2003;
108
2851-2856
- 8
Arnold A E, Simoons M L, van de Werf F. et al .
Recombinant tissue-type plasminogen activator and immediate angioplasty in actue myocardial
infarction: one-year follow-up.
Circulation.
1992;
86
111-120
- 9
SWIFT (Should we intervene following thrombolysis?) trial study group.
SWIFT trial of delayed elective intervention vs. Conservative treatment after thrombolysis
with anistreplase in acute myocardial infarction.
BMJ.
1991;
302
555-560
- 10
TIMI Study group.
Comparison of invasive and conservative strategies after treatment with intravenous
tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis
in myocardial infarction phase II trial.
N Engl J Med.
1989;
320
618-627
- 11
Fernandez-Aviles F, Alonso J J, Castro-Beiras A. et al, for the GRACIA group .
Routine invasive strategy within 24 hours of thrombolysis versus ischemia-guided conservative
approach for actue myocardial infarction with ST-segment elevation (GRACIA-1): a randomised
controlled trial.
Lancet.
2004;
364
1045-1053
- 12
Montalescot G, Barragan P, Wittenberg O. et al, for the ADMIRAL investigators .
Platelet Glykoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial
infarction.
N Engl J Med.
2001;
344
1985-1993
- 13
Gyöngyösi M, Domanovits H, Benzer W. et al, for the Reo PRO-BRIDGING study group .
Use of abciximab prior to primary angioplasty in STEMI results in earlier recanalization
of the infarct-related artery and improved myocardial tissue reperfusion - Results
of the Austrian multi-centre randomized ReoPRO-BRIDGING study.
Eur Heart J.
2004;
25
2125-2133
- 14
Montalescot G, Borentain M, Payot L, Collet J P, Thomas D.
Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous
coronary intervention of acute ST-segment elevation myocardial infarction: A meta-analysis.
JAMA.
2004;
292
362-366
- 15
Zijlstra F, Ernst N, de Boer M-J. et al .
Influence of prehospital administration of aspirin and heparin on the initial patency
of the infarct-related artery in patients with acute ST elevation myocardial infarction.
J Am Coll Cardiol.
2002;
39
1733-1737
- 16
The CURE Investigators.
Effects of Clopidogrel in addition to Aspirin in patients with acute coronary syndromes
without ST-segment elevation.
N Engl J Med.
2001;
345
494-502
Dr. Gregor Simonis
Medizinische Klinik/Kardiologie · Technische Universität Dresden
Fetscherstr. 76 · 01307 Dresden
Phone: 03 51/4 50-17 01
Fax: 03 51/4 50-17 02
Email: gsimonis@gmx.de
